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ABSTRACT
Background and the purpose of the study: The available literatures show that 5-HT1A receptors are 
widely distributed throughout the basal ganglia, and their activation facilitate dopamine release. 
Neuroleptic drugs such as haloperidol induce Parkinson-like syndrome through blocking brain 
D2 receptors. This study aimed to investigate effect of buspirone, a partial agonist of 5HT1A 
receptor, on motor dysfunctions induced by haloperidol  and involvement of 5HT1A  receptors 
in this regard. 
Methods: Study was performed on the male mice weighing 25-30 g. Animals were divided 
randomly to groups of 10 animals. Motor dysfunction  was induced by  intraperitoneal (i.p.) 
injection of haloperidol (1 mg/kg). Catalepsy was assayed by bar-test method 5, 60, 120 and 180 
minutes after drug administration and motor imbalance was studied by rotarod test. 
Results  and  major  conclusion:  Results  showed  that  buspirone  (20  mg/kg,  i.p.)  decreased 
significantly haloperidol-induced catalepsy and balance disorder in a dose dependent manner.   
Furthermore,  8-OH-DPAT  (10  mg/kg,  i.p.),    as  an  agonist  of  5-HT1A  receptor,  decreased 
haloperidol-induced catalepsy and balance disorder. The effect of buspirone (20 mg/kg, i.p.) on 
haloperidol-induced motor disorders  was abolished by NAN-190 (10 mg/kg, i.p.), as a 5-HT1A 
receptor antagonist. From the results it may be concluded that buspirone improves haloperidol-
induced catalepsy and balance disorder through activation of 5-HT1A receptors.  
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INTRODUCTION
Parkinson’s Disease (PD) is a progressive  neuro-
degenerative  disease occurring  in  approximately1% 
of the population of  age over  50 years. It’s most 
prominent symptoms are tremor, muscle stiffness and 
bradykinesia.  Some  non-motor  symptoms  such  as 
cognitive behavior disorder and depression are usually 
observed in patients.  The disease is accompanied by 
preferential  loss  of  dopaminergic  neurons  of  the 
substanitia  nigra  pars  compacta  (SNc)  (1)  and  the 
influence of other neurotransmitter systems have not 
been  studied  extensively. The  fact  that  serotonergic 
system are also involved in PD has been raised from 
previous studies (2) and postmortem research has shown 
reduced levels of basal ganglia serotonin (5-HT) as well 
as its metabolite 5-hydroxy-indoleatic acid (5HIAA) 
(3). While there are some reports on the inhibitory 
effect of  5-HT  on striatal dopamine (DA)  release 
(4) , other studies have shown that 5-HT facilitates 
DA  outflow  (5).  This  discrepancy  results  from 
differencs in receptor types and subtypes (6).
5-HT1A receptors are widely distributed throught the 
basal ganglia (7). They are located on dorsal raphe 
neurons with efferents to the striatum, and are also 
localized on cortical neurons sending glutamatergic 
projections to the basal ganglia (1). Studies have 
shown  that  5-HT1A  receptor  stimulation  Showed 
antiparkinsonian  effects  in  6-hydroxydopamine 
(6-OHDA)- lesioned rats (8). This effect is most likely 
caused by the increase in 5-HT1A receptor activation, 
resulting in  inhibition of serotonin release (1). Although 
stimulation of 5-HT1A receptor is associated with an 
increase in dopamine turnover (9), dopaminergic cell 
firing (10) and dopamine release (11), suggesting that 
5-HT1A agonists might have potential therapeutic value 
in the treatment of parkinson’s disease,  Other studies 
have  reported  that  administration  of  the  5-HT1A 
agonist did not affect basal DA release in the nucleus 
accumbens or the striatum (4,12).
In animal studies, neurotoxins such as 1-methyl-4-
phenyl-1,2,3,6-tetrahydroxypyridine  (MPTP)  and 
6-OHDA  and  neuroleptic  drugs  (e.g.  haloperidol) 
are used commonly to create experimental model 
of PD by which certain aspects of the disease such 
as  catalepsy,  motor  imbalance  and  slowing  of 
movement can be modeled (1,13). The cataleptic 
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end point of catalepsy was considered the time that   
both front paws were removed from the bar or if the 
animal moved its head in an exploratory manner. A 
cut-off time of 720 seconds was applied (15). 
The rotarod test was used to assess the ability of 
the animal to maintain balance on a 1-inch diameter 
rod  revolving  at  a  constant  rate  of  6  revolutions 
per minute (16). This test requires a high degree of 
sensorimotor coordination and is therefore used to 
test  more  subtle  neurological  deficits. The  ability 
of all animals to pass the rotarod test was checked 
regularly prior and after drug administration. 
Expression of data and statistics
Descriptive statistics and comparisons of differences 
between  each  data  set  were  calculated  by  use  of 
InStat software. The data were expressed as mean 
±  SEM,  and  were  analyzed  by  one-way ANOVA 
in  each  experiment.  Statistical  significance  was 
accepted  at  the  level  of  p<0.05.  In  the  case  of 
significant  variation  (p<0.05),  the  values  were 
compared by Tukey test.
RESULTS
Effect of buspirone on haloperidol-induced motor 
impairment
Six  groups  of  mice  were  treated  with  saline, 
haloperidol (1 mg/kg, i.p.) alone and haloperidol (1 
mg/kg, i.p.) with four different doses of buspirone 
(5, 7.5, 10 and 20 mg/kg, i.p.). As it has been shown 
in figure 1A and 1B,  haloperidol was able to induce 
significant (p<0.001) catalepsy and motor imbalance 
(p<0.001)  when compared with saline-treated mice. 
Buspirone , as a partial agonist of 5-HT1A receptors, 
reduced  haloperidol-induced  catalepsy  (p<0.001, 
0.01, 0.05) almost in a dose dependent manner (Fig. 
1A). Results showed that buspirone (20 mg/kg, i.p.) 
improves markedly (p<0.001) haloperidol induced 
motor imbalance (Fig. 1B). 
Effect of 8-OH-DPAT on haloperidol-induced motor 
impairment
The  effect  of  8-OH-DPAT  (10  mg/kg,  i.p.)  on 
haloperidol-induced catalepsy and motor 2 imbalnce 
was determined. Results showed that 8-OH-DPAT 
attenuated haloperidol-induced catalepsy (p<0.001) 
and motor imbalance (p<0.001) in comparision with 
haloperidol alone. In group of animals treated with 
8-OH-DPAT alone, there was not any remarkable 
alteration in bar test and rotarod elapsed time (Fig. 
2A, 2B).
Effect  of  buspirone  and  NAN-190  co-injection  on 
haloperidol-induced motor impairment
As  it  has  been  shown  in  figure  3A,  NAN-190  (10 
mg.kg, i.p.) as a 5-HT1A receptor antagonist, abolished 
(p<0.001, 0.05) anticataleptic effect of buspirone (20 
mg/kg, i.p.). This drug also decreased (p<0.001, 0.01) 
immobility induced in rodents by typical neuroleptics 
(e.g., haloperidol, chlorpromazine, fluphenazine) is 
a behavioral method to study nigrostriatal function 
and  its  modulation  by  other  neurotransmitters 
(14).  Drugs  which  attenuate  haloperidol-induced 
motor  disorders  might  reduce  the  extrapyramidal 
signs of PD (15). Thus investigation of the effects 
of buspirone on  extrapyramidal  side effects of   
haloperidol  appeared of  interest.  The present study 
was designed to  determine effect of buspirone on 
catalepsy and motor imbalance induced by haloperidol   
as well as possible involvement of 5-HT1A receptors 
by using 8-OH-DPAT and NAN-190 as agonist and 
antagonist of 5-HT1A recepotrs respectively.
MATERIAL  AND  METHODS
Chemicals
All chemicals were obtained from Sigma Chemical 
Company (USA) except for busprione and haloperidol 
that  were  purchased  from  Heumann  Company 
(Germany)  and  Daru-Pakhsh  Company  (Iran) 
respectively.
Solutions  were  prepared  fresh  on  the  days  of 
experimentation by dissolving drugs in physiological 
saline  (0.9%  NaCl).  The  drugs  were  injected 
intraperitonealy  (i.p.)  and  movement  disorders 
were assessed by bar test and rotarod of 5, 60, 120 
and 180 min after drugs administration.
Animals
The experiments were carried out on male Swiss 
albino mice weighing 25-30 g. Animals were housed 
in  standard  polypropylene  cages,  ten  per  cage, 
under a 12:12 h light/dark schedule at an ambient 
temperature of 23±2 °C and had access to food and 
water freely. All experiments were carried out under 
the  ethical  guidelines  of  the Tabriz  University  of 
Medical Sciences, for the care and use of laboratory 
animals (National Institutes of Health Publication 
No 85-23, revised 1985).
Motor impairment study
Motor impairment was induced with haloperidol  (1 mg/
kg, ip) and measured by bar test and rotarod methods 
at 5, 60, 120 and 180 minute after drug administration. 
In each tests animals were used only once. The dose 
of the  haloperidol was chosen to produce a moderate 
degree of catalepsy and motor imbalance, so that either 
attenuation or potentiation of the both phenomenon 
could be detected (15). The drugs (and saline for the 
controls)  were  injected  ip  with  a  29-G  needle,  15 
min before haloperidol. All observations were made 
between 9:00 AM and 16:00 PM in a quiet room by an 
observer who was blind to treatments.
Catalepsy was measured by means of a standard bar 
test, as the time that mouse maintained an imposed 
position with both front limbs extended and resting 
on a 3-cm high wood bar (0.9 cm in diameter). The Buspirone improves haloperidol-induced motor disorders 43
the effect of buspirone (20 mg/kg, i.p.) on haloperidol-
induced motor imbalance (Fig. 3B). 
DISCUSSION
Parkinson's disease is caused by degeneration of 
dopaminergic  neurons  of  substantia  nigra,  pars 
compacta. The most important characteristic of this 
disease is reduction of dopamine release from the 
end of striatal dopaminergic nerves. This disease is 
accompanied  with  movement  disorders  e.g.  tremor, 
muscle rigidity and slow movement (1). Some 
neurotoxins  such  as  MPTP,  6-OHDA,  or  neuroleptic 
drugs  (e.g.  haloperidol)  are  used  frequently  to 
create  experimental  models  of  this  disease  (1, 
13). In  this study effect of buspirone and possible 
involvement of 5-HT1A receptors on haloperidol-induced 
catalepsy and motor imbalance was investigated. 
Bar test (15) and rotarod  (17) are standard tests 
that are usually used to evaluate catalepsy and 
motor imbalance disoreders, respectively. Results 
of this study showed that acute administration of 
haloperidole induced catalpsy and imbalance in the 
rotating rod (rotarod) which is in accordance with 
results of other studies (13) where haloperidol (D2 
antagonist) was used to create an empirical model of 
Parkinson disease.
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Fig. 1. Effects of buspirone (5, 7.5, 10 and 20 mg/kg, i.p.) on haloperidol-induced motor 
impairment (A: Bar test, B: Rotarod). Each bar represents the mean±SEM of elapsed time (s), 
n=10 mice for each group. a:p<0.001 vs saline group; b: p<0.001, c: p<0.01 and d p<0.05 vs
haloperidol treated group. B= buspirone 
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Fig. 2. Effect of 8-OH-DPAT (10 mg/kg, i.p.) on haloperidol-induced motor impairment (A:
Bar test, B: Rotarod). Each bar represents the mean±SEM of elapsed time (s), n=10 mice for 
each group. a: p<0.001 vs saline group, b: p<0.001 vs haloperidol treated group.
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Buspirone, as a partial agonist of 5-HT1A receptors, 
improved prominently haloperidol-induced catalepsy 
and  motor  imbalance.  This  finding  substantiates 
studies reporting that 5-HT1A receptor agonists 
attenuate movement disorders induced by dopamine 
neurotoxins which was  assessed by other experimental 
methods (18). Haloperidol is a potent typical neuroleptic 
drug which is used for treatment of some neuropsy-
chiatric  diseases.  Parkinson-like  syndromes  and 
extrapyramidal symptoms are the major problems 
resulting from the use of this drug in psychotic patients 
(19). Therefore, special attention are paied to adjuvant 
therapy to reduce the severity of motor complications 
induced by haloperidol or any other neuroleptic drugs. 
Apart  from  affecting  5-HT1A  receptors,  buspirone 
has  also  D2  and  α2-adrenoceptor  blocking  effects 
(20, 21). Therefore, it is possibile that its effects 
on improvement of haloperidol induced motor 
deficiency may be due to its effects on these  receptors. 
In this study it was shown  that 8-OH-DPAT could 
reduce  haloperidol-induced  movement  disorders 
considerably  and  NAN-190  (5-HT1A  antagonist) 
abolished improving effect of buspirone on motor 
disorders induced by haloperidol. It might be due to 
effects of buspirone on  and as a result  involvement 
of á2 or D2 receptors may be neglected. 
It has been shown that the 5-HT1A receptor is present 
on  dorsal  raphe  neurons  with  efferents  to  the 
striatum, and on cortical neurons sending gluta-
matergic projections to the basal ganglia (1). Stimulation 
of 5-HT1A receptors in these regions leads to decrease 
and increase of serotonin and dopamine release 
respectively (9) by the inhibition of adenyl cyclase   
and opening of potassium channels (22). Therefore, 
it  may be suggested that the effect of buspirone on 
haloperidol-induced  motor  disorders  is  due  to 
decrease of inhibitory effects of serotonin on the 
release of dopamine. 
Anxiety is a co-morbid problem that is observed 
commonly  in  patients  suffering  from  psychosis 
(23). Therefore, adjuvant therapy with buspirone in 
addition of reducing symptoms of anxiety, might 
be decrease in movement complications induced by 
haloperidol or other neuroleptic drugs. On the basis 
of results of this study further  investigation on a 
possible  usefulness of buspirone in decreasing motor 
side effects of neuroleptic drugs is suggested.  
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